Your trusted source for investing success

Tag: clinical trials

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

Abeona Therapeutics (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation (EMA/OD/013/18) for Abeona’s gene therapy program ABO-202 for the treatment of

Biomerica Announces Third Quarter Financial Results

Biomerica (Nasdaq:BMRA) today reported net sales of $4,433,785 for the nine months ending February 28, 2018, compared to $4,342,247 for the period ended February 28, 2017. Sales for the three months ending February 28, 2018 were $1,375,666 compared to $1,499,930 for the period ended February 28, 2017.

As quoted in the

Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the presentation of new data for APVO436, a bispecific antibody candidate targeting CD123 and CD3, at the American Association for Cancer Research (AACR) 2018 Annual Meeting. The preclinical data demonstrate potent T-cell cytotoxicity of tumors

Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125

Idera Pharmaceuticals (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases, today announced it has entered into a clinical development support agreement with Pillar Partners Foundation.  Under the terms of the agreement Pillar Partners will provide direct funding

EyeGate Announces $11.25 Million Public Offering

EyeGate Pharmaceuticals (NASDAQ:EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today the pricing of a public offering of an aggregate of 35,156,250 shares of common stock (or common stock equivalents) and warrants to purchase an aggregate of 35,156,250

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Pharmaceutical Update: Q1 in Review

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/pharmaceutical-update-q1-review/